We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Device Facilitates Removal of Esophageal Precancerous Tissue

By HospiMedica International staff writers
Posted on 14 Oct 2015
A new endoscopic mucosal resection (EMR) device offers a minimally invasive alternative to esophagectomy in the upper gastrointestinal (GI) tract.

The Captivator EMR system has been specifically designed for ligation-assisted EMR of the upper GI via an access port that provides physicians with enhanced visualization, control, and easy passage of 7Fr tools, such as the Interject sclerotherapy needle and the Resolution clip for prophylacix following resection. More...
The system includes a captivator snare and band ligator to snare either above or below the band; and a pathology kit enables histological processing of tissue samples for staging and removal of precancerous tissue during an endoscopic outpatient procedure.

The system has been specifically designed to provide physicians with a 360 degree unobstructed peripheral view and complete visualization of the diseased area when performing resections, thanks to a band ligator cap that does not obstruct the ligator bands. The device handle provides a tactile and audible feedback to signal when a band has deployed. The Captivator EMR system is a product of Boston Scientific (Natick, MA, USA) and it is available in the United States, Europe, Singapore, Australia, and Puerto Rico.

“The Captivator EMR device provides improved endoscopic visualization, so the resection can be better directed to the area of interest,” said professor of gastrointestinal endoscopy Jacques Bergman, MD, of University of Amsterdam (The Netherlands). “The enhanced view, along with easy passage of accessory devices and the ability to use compatible hemostatic devices to manage potential bleeding and complications may enable a safer endoscopic resection.”

“As a leader in GI endoscopic devices, this launch complements our existing product offering for lower GI EMR procedures, and expands our portfolio into the growing upper GI EMR segment,” said David Pierce, senior vice president and president of endoscopy at Boston Scientific. “The Captivator EMR Device provides physicians and patients with an important new option for staging and treating early esophageal neoplasia and cancer.”

EMR was first developed in Japan for the treatment of early gastric cancer and has since spread in use throughout the world for various indications, including dysplastic Barrett mucosa and sessile colonic neoplasms.

Related Links:

Boston Scientific



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.